Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma
Open Access
- 11 February 2002
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 86 (3) , 417-423
- https://doi.org/10.1038/sj.bjc.6600075
Abstract
In serum, the major part of vascular endothelial growth factor derives from in vitro degranulation of granulocytes and platelets. Therefore, plasma may be preferred for vascular endothelial growth factor measurements. However, which specimen is the best predictor of survival is still debated. The present study analyzed the prognostic value of matched preoperative serum and plasma vascular endothelial growth factor concentrations in patients with colorectal cancer. To establish the reference range among healthy people, vascular endothelial growth factor was analyzed in 50 matched EDTA-plasma and serum samples from healthy blood donors. Preoperatively, in 524 patients with colorectal cancer, matched plasma and serum vascular endothelial growth factor concentrations were analyzed. In the colorectal cancer patients, the median plasma vascular endothelial growth factor concentration (44 pg ml−1) was significantly (P=0.01) higher than the median plasma vascular endothelial growth factor concentration (30 pg ml−1) in the healthy blood donors. In serum, no significant (P=0.30) difference in the median vascular endothelial growth factor concentration was found between colorectal cancer patients (268 pg ml−1) and healthy blood donors (220 pg ml−1). The preoperative vascular endothelial growth factor concentrations were dichotomized by the 95th percentile of the healthy blood donors (plasma=112 pg ml−1, serum=533 pg ml−1). In univariate survival analyses, both high plasma vascular endothelial growth factor (>112 pg ml−1) and high serum vascular endothelial growth factor (>533 pg ml−1) predicted a reduced survival. In multivariate survival analyses, high serum vascular endothelial growth factor (>533 pg ml−1) independently predicted a reduced survival (HR=1.65, P=0.015), while high plasma vascular endothelial growth factor (>112 pg ml−1) did not (HR=1.27, P=0.23). This study indicates that preoperative serum vascular endothelial growth factor apparently is a better predictor of overall survival than the preoperative plasma vascular endothelial growth factor.Keywords
This publication has 12 references indexed in Scilit:
- Relationship between plasma levels of vascular endothelial growth factor and serum levels of interleukin-12 in patients with colorectal cancer.2000
- Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancerBritish Journal of Cancer, 2000
- Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinomaEuropean Journal of Surgical Oncology, 2000
- Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging?2000
- Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen?International Journal of Oncology, 2000
- The Hemostatic System as a Regulator of AngiogenesisPublished by Elsevier ,2000
- Soluble vascular endothelial growth factor in various blood transfusion componentsTransfusion, 1999
- Inhibition of Metastases by AnticoagulantsJNCI Journal of the National Cancer Institute, 1999
- Vascular Endothelial Growth Factor (VEGF) is Released from Platelets during Blood Clotting: Implications for Measurement of Circulating VEGF Levels in Clinical DiseaseClinical Science, 1998
- Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biologyBritish Journal of Cancer, 1998